We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Idenix Confident in Hep C Drugs’ Safety Advantage Despite Trial Holds
Idenix Confident in Hep C Drugs’ Safety Advantage Despite Trial Holds
August 29, 2012
The FDA has placed a “precautionary” clinical hold on Idenix Pharmaceuticals’ next-generation nucleotide polymerase inhibitor, IDX19368, being developed to treat hepatitis C (HCV) infection.